Glenmark Pharmaceuticals Ltd. has delivered on its regional out-licensing plans. It has struck a deal with the Shanghai-based start-up Harbour BioMed for its lead immuno-oncology candidate. (Also see "Glenmark Sets Sights On Regional Out-Licensing, Lot Riding On US Rhinitis NDA" - Scrip, 31 May, 2018.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?